Semaglutide SEMA

An FDA-approved medication for diabetes (Ozempic) and obesity (Wegovy), one of the most extensively studied drugs in modern medicine. Landmark human trials confirm substantial weight loss and meaningfully lower heart-disease risk, with nausea and other stomach issues as the most common complaints.

Also known as Ozempic, Wegovy, Rybelsus, NN 9535, NNC 0113-0217, 53AXN4NNHX, CHEBI:167574

Effects Lose fat

Routes Oral Subcutaneous

Legal status Prescription drug

WADA Not listed

Molecular Structure of C₁₈₇H₂₉₁N₄₅O₅₉

Drag to rotate · scroll to zoom

PubChem has no 3D conformer for this molecule, so this is the flat structure.

Chemistry

Formula: C187H291N45O59
Molar mass: 4114
CAS: 910463-68-2
PubChem CID: 56843331
IUPAC name: 18-[[(1R)-4-[2-[2-[2-[2-[2-[2-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-2-methylpropanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-18-oxooctadecanoic acid
InChIKey: DLSWIYLPEUIQAV-CCUURXOWSA-N

Reported dosing

Approved label

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 1-2 mg once weekly (diabetes) or 2.4 mg once weekly (weight management)

Reported range 0.25-2.4 mg once weekly, titrated; oral formulation 7-25 mg once daily

Route Subcutaneous injection (or oral tablet for one formulation)

Frequency Once weekly (injectable) or once daily (oral)

Duration Chronic/ongoing (as prescribed)

FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for diabetes, Wegovy for weight management). Compounded 'generic' versions sold by some telehealth/gray-market sources are not FDA-approved as standardized products.

Where this comes from FDA prescribing information

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.

Variants

Name	Abbr	Route	Notes
Semaglutide injection	SEMA-I	Subcutaneous	The Ozempic and Wegovy form, once weekly.
Semaglutide oral	SEMA-O	Oral	The Rybelsus tablet, taken daily on an empty stomach.